Pharmacological studies on synthetic flavonoids: Comparison with diazepam

Neuropharmacology

Volumn 38, Issue 7, 1999, Pages 965-977

  Griebel, Guy ^a   Perrault, Ghislaine ^a   Tan, Suon ^a   Schoemaker, Hans ^a   Sanger, David J ^a  

^a SANOFI   (France)

Author keywords

Anxiety; Benzodiazepines; Binding; Conflict tests; Convulsions; Defensive behaviors; Diazepam; Drug discrimination; Exploration models; Flavonoids; Flumazenil

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 6 BROMO 3' NITROFLAVONE; 6 BROMOFLAVONE; CHLORDIAZEPOXIDE; DIAZEPAM; FLAVONOID; FLUMAZENIL; ISONIAZID; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; ZOLPIDEM;

ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR; CEREBELLUM; CLONIC SEIZURE; CONFLICT; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD;

ANIMALS; ANTI-ANXIETY AGENTS; AVOIDANCE LEARNING; DIAZEPAM; DISCRIMINATION LEARNING; ESCAPE REACTION; FLAVONOIDS; ISONIAZID; LIGHT; MALE; MAZE LEARNING; MOTOR ACTIVITY; PUNISHMENT; RATS; RATS, WISTAR; RECEPTORS, GABA-A; RISK ASSESSMENT; SEIZURES;

EID: 0033008340     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(99)00026-X     Document Type: Article

References (47)

1. Barrett J.E., Brady L.S., Witkin J.M. Behavioral studies with anxiolytic drugs. I. Interactions of the benzodiazepine antagonist Ro 15-1788 with chlordiazepoxide, pentobarbital and ethanol. J. Pharmacol. Exp. Ther. 233:1985;554-559.
2. Belzung C., Le Pape G. Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety. Physiol. Behav. 56:1994;623-628.
3. Benavides J., Abadie P., Baron J.C., Scatton B. In vivo interaction of zolpidem with omega (benzodiazepine) site subtypes. Freeman H., Puech A.J., Roth T. Zolpidem: an Update of Its Pharmacological Properties and Therapeutic Place in the Management of Insomnia. 1996;33-43 Editions Scientifiques, Paris.
4. Blanchard D.C., Griebel G., Rodgers R.J., Blanchard R.J. Benzodiazepine and serotonergic modulation of antipredator and conspecific defense. Neurosci. Biobehav. Rev. 22:1998;597-612.
5. Blanchard R.J., Griebel G., Henrie J.A., Blanchard D.C. Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci. Biobehav. Rev. 21:1997;783-789.
6. Braestrup C., Nielsen M. Multiple benzodiazepine receptors. Trends Neurosci. 3:1980;301-303.
7. A receptors. J. Pharmacol. Exp. Ther. 266:1993;1018-1028.
8. Griebel G., Blanchard D.C., Jung A., Blanchard R.J. A model of 'antipredator' defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behav. Pharmacol. 6:1995;732-745.
9. Griebel G., Blanchard D.C., Blanchard R.J. Predator-elicited flight responses in Swiss-Webster an experimental model of panic attacks. Prog. Neuro-Psych. Biol. Psych. 20:1996;185-205.
10. Griebel G., Sanger D.J., Perrault G. The use of the rat elevated plus-maze to discriminate between non- selective and BZ-1 (ω1) selective, benzodiazepine receptor ligands. Psychopharmacology. 124:1996;245-254.
11. Griebel G., Perrault G., Sanger D.J. Limited anxiolytic-like effects of non-benzodiazepine hypnotics in rodents. J. Psychopharmacol. 12:1998;356-365.
12. Griebel, G., Perrault, G., Tan, S., Schoemaker, H., Sanger, D.J., 1998b. Comparison of the pharmacological properties of classical and novel BZ-ω receptor ligands. Behav. Pharmacol. (submitted).
13. Hodges H., Green S. Are the effects of benzodiazepines on discrimination and punishment dissociable? Physiol. Behav. 41:1987;257-264.
14. Kapczinski F., Curran H.V., Gray J., Lader M. Flumazenil has an anxiolytic effect in simulated stress. Psychopharmacology. 114:1994;187-189.
15. Lader M. Benzodiazepines: a risk-benefit profile. CNS Drugs. 1:1994;377-387.
16. Lal H., Harris C. Interoceptive stimuli produced by an anxiogenic drug are mimicked by benzodiazepine antagonists in rats pretreated with isoniazid. Neuropharmacology. 24:1985;677-679.
17. Langer S.Z., Arbilla S. Imidazopyridines as a tool for the characterization of benzodiazepine receptors: a proposal for a pharmacological classification as omega receptor subtypes. Pharmacol. Biochem. Behav. 29:1988;763-766.
18. Löscher W., Frey H.H. Effect of convulsant and anticonvulsant agents on level and metabolism of gamma-aminobutyric acid in mouse brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 296:1977;263-269.
19. Mao C.C., Guidotti A., Costa E. Evidence for an involvement of GABA in the mediation of the cerebellar cGMP decrease and the anticonvulsant action diazepam. Naunyn-Schmiedeberg's Arch. Pharmacol. 289:1975;369-378.
20. Marder M., Viola H., Wasowski C. et al. 6,3′-Dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties. Bioorg. Medicinal. Chem. Lett. 5:1995;2717-2720.
21. Marder M., Viola H., Wasowski C. et al. 6-Bromoflavone, a high affinity ligand for the central benzodiazepine receptors is a member of a family of active flavonoids. Biochem. Biophys. Res. Commun. 223:1996;384-389.
22. Martin J.R., Pieri L., Bonetti E.P. et al. Ro 16-6028: a novel anxiolytic acting as a partial agonist at the benzodiazepine receptor. Pharmacopsychiatry. 21:1988;360-362.
23. Medina J.H., Viola H., Wolfman C. et al. Overview - flavonoids: a new family of benzodiazepine receptor ligands. Neurochem. Res. 22:1997;419-425.
24. Medina J.H., Viola H., Wolfman C. et al. Neuroactive flavonoids: new ligands for the Benzodiazepine receptors. Phytomedicine. 5:1998;235-243.
25. Misslin R., Belzung C., Vogel E. Behavioural validation of a light/dark choice procedure for testing anti-anxiety agents. Behav. Process. 8:1989;119-132.
26. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods. 14:1985;149-167.
27. Pellow S., File S.E. The effects of putative anxiogenic compounds (FG 7142, CGS 8216 and Ro 15-1788) on the rat corticosterone response. Physiol. Behav. 35:1985;587-590.
28. Pokk P., Zharkovsky Z. The effects of flumazenil, Ro 15-4513 and beta-CCM on the behaviour of control and stressed mice in the plus-maze test. J. Physiol. Pharmacol. 48:1997;253-261.
29. A/benzodiazepine receptor complex in the rat nervous system. J. Neurochem. 58:1992;485-493.
30. Sanger D.J., Joly D., Zivkovic B. Behavioral effects of nonbenzodiazepine anxiolytic drugs: a comparison of CGS 9896 and zopiclone with chlordiazepoxide. J. Pharmacol. Exp. Ther. 232:1985;831-837.
31. Sanger D.J. Discriminative stimulus properties of anxiolytic and sedative drugs: pharmacological specificity. Psychopharmacol. Ser. 4:1988;73-84.
32. Sanger D.J. The behavioural effects of novel benzodiazepine (ω) receptor agonists and partial agonists: Increases in punished responding and antagonism of the pentylenetetrazole cue. Behav. Pharmacol. 6:1995;116-126.
33. Sanger D.J., Zivkovic B. The discriminative stimulus properties of zolpidem, a novel imidazopyridine hypnotic. Psychopharmacology. 89:1986;317-322.
34. Sanger D.J., Zivkovic B. Discriminative stimulus effects of alpidem, a new imidazopyridine anxiolytic. Psychopharmacology. 113:1994;395-403.
35. Schoemaker H., Claustre Y., Fage D. et al. Neurochemical characteristics of amisulpride, an atypical dopamine D-2/D-3 receptor antagonist with both presynaptic and limbic selectivity. J. Pharmacol. Exp. Ther. 280:1997;83-97.
36. Sieghart W., Schuster A. Affinity of various ligands for benzodiazepine receptors in rat cerebellum and hippocampus. Pharmacol. Biochem. Behav. 33:1984;4033-4038.
37. Squires R.F., Benson D.I., Braestrup C. et al. Some properties of brain specific benzodiazepine receptors: new evidence for multiple receptors. Pharmacol. Biochem. Behav. 10:1979;825-830.
38. Stephens D.N., Schneider H.H., Kehr W. et al. Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors. J. Pharmacol. Exp. Ther. 253:1990;334-343.
39. 3H]flumazenil binding to the native a5-containing omega/benzodiazepine receptor subtype in rat brain. Can. J. Physiol. Pharmacol. 72:1994;448.
40. Urbancic M., Gadek M.A., Marczynski T.J. Chronic exposure to flumazenil: anxiolytic effect and increased exploratory behavior. Pharmacol. Biochem. Behav. 35:1990;503-509.
41. Viola H., Marder M., Wolfman C., Wasowski C., Medina J.H., Paladini A.C. 6-Bromo-3′-nitroflavone, a new high affinity benzodiazepine receptor agonist recognizes two populations of cerebral cortical binding sites. Bioorg. Medicinal. Chem. Letter. 7:1997;373-378.
42. Vogel J.R., Beer B., Clody D.E. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia. 21:1971;1-7.
43. Wolfman C., Viola H., Paladini A., Dajas F., Medina J.H. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol. Biochem. Behav. 47:1994;1-4.
44. Wolfman C., Viola H., Marder M. et al. Anxioselective properties of 6,3′-dinitroflavone, a high-affinity benzodiazepine receptor ligand. Eur. J. Pharmacol. 318:1996;23-30.
45. Wolfman C., Viola H., Marder M. et al. Pharmacological characterization of 6-bromo-3′-nitroflavone, a synthetic flavonoid with high affinity for the benzodiazepine receptors. Pharmacol. Biochem. Behav. 61:1998;239-246.
46. Zivkovic B., Morel E., Joly D., Perrault G., Sanger D.J., Lloyd K.G. Pharmacological and behavioral profile of alpidem as an anxiolytic. Pharmacopsychiatry. 23(Suppl. 3):1990;108-113.
47. Zivkovic B., Perrault G., Sanger D. Receptor subtype-selective drugs: a new generation of anxiolytics and hypnotics. Mendlewitz J., Racagni G. Target Receptors for Anxiolytics and Hypnotics: From Molecular Pharmacology to Therapeutics. 1992;55-73 Karger, Basel.